Vor Biopharma
54 hedge funds and large institutions have $33.5M invested in Vor Biopharma in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 20 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.5% less ownership
Funds ownership: 3.99% → 3.5% (-0.5%)
24% less funds holding
Funds holding: 71 → 54 (-17)
39% less capital invested
Capital invested by funds: $54.5M → $33.5M (-$21.1M)
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
65% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.25M |
| 2 |
CAC
Cowen and Company
New York
|
+$1.11M |
| 3 |
Renaissance Technologies
New York
|
+$238K |
| 4 |
Two Sigma Investments
New York
|
+$125K |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$69.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$6.46M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$2.28M |
| 3 |
Goldman Sachs
New York
|
-$316K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$247K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$244K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Group One Trading
Chicago,
Illinois
| – | -$201 | -11 | Closed |
|
|
SAM
77
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$116 | -5 | Closed |
|
78
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$55 | +3 | New |
|
VOR Hedge Fund Activity: Q3 2024 in Review
54 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q3 2024, worth a combined $33.5M — down 39% from $54.5M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of VOR and 9 opened new positions — a net loss of 17 holders — while 20 trimmed existing stakes and 8 added.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $2.25M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $6.46M sold.
- 54 institutional investors held Vor Biopharma (VOR) as of Q3 2024, down from 71 in Q2 2024.
- Funds reported $33.5M of Vor Biopharma stock for Q3 2024, down 39% quarter-over-quarter.
- 9 funds opened new Vor Biopharma positions in Q3 2024 and 26 closed out, a net change of -17 holders.
- The largest Vor Biopharma buyer in Q3 2024 was Hudson Bay Capital Management, an estimated $2.25M added.
- The largest Vor Biopharma seller in Q3 2024 was Paradigm Biocapital Advisors, an estimated $6.46M sold.
Based on aggregated 13F filings for Q3 2024.